



Nomor Dokumen	: FORM7.8V02
---------------	--------------

Certificate of Analysis

Report Number : 004/CERT-BRI/II/2026

COC ID : -

Quotation ID : -

Number of Pages : 5 Including Cover

Customer Sample(s) Identity : -

Lab Sample ID : -

Priority : Normal / ~~Urgent~~

Date of Sample(s) Received : 06th February 2026

Date of Analysis Finished : 09th February 2026

Customer : PT. Invilab Biosains Indonesia

Customer Category : Company / ~~Government Institution~~ / School/ University
~~Private Individual~~ / Others

Customer Contact Person : *invilabbiosains@gmail.com*

Approved by,

BIOTEK REKAYASA INDONESIA
Firmansyah Karim
Director

Monday, 09th February 2026

Terms and Conditions

a) This report may not be reproduced for any reason except in full and with permission from PT Biotek Rekayasa Indonesia; **b)** In any case PT Biotek Rekayasa Indonesia is not responsible for misuse of the contents of this report; **c)** This report related only to sample(s) received and analyzed if sampling procedure has been done by other party(ies); **d)** If Sample(s) had already taken by other party(ies) or taken not in accordance with the stated method, the report result related to ISO/IEC 17025 accreditation requirements will be affected as described in the quotation previously agreed; **e)** Any complaint will be responded immediately within 48 hours. Complaint received within 2 months after this Report received by the Customer will be followed up as soon as possible. Complaints coming afterwards will not be guaranteed; **f)** Samples will be disposed one month after Customer received this Report (unless requested to be returned upon agreement); **g)** This report contain marks in the form of singular number within bracket and other form of marks that need to be known, as follows:

• (1) is sign for subcontracted test parameter; • (2) is sign for non accredited test parameter or test parameter become unaccredited due to different sample matrix; • (3) is sign for parameter related to sample(s) taken not in accordance with the stated method as described in point d; (4) is sign for in situ test parameter; • NA mean Not Available or Not Applicable




Certificate of Analysis

I Sample Description

- 1.1 Subject : E.KRATOM 25 ppm
1.2 Batch Number : -
1.3 Expired Date : -
1.4 Customer Sample(s) Identity : -
1.5 Lab Sample ID : -
1.6 Matrix : Powder

II Results

No.	Parameters	Units	Results	Method
1.	Mitragynine	%	91,65	BRI-IK-LAB-006V01 (UHPLC)



This report may not be reproduced for any reason except in full and with permission from PT Biotek Rekayasa Indonesia
Please read full-length Terms and Conditions in the first page




Certificate of Analysis

I Sample Description

- 1.1 Subject : E.KRATOM 25 ppm
1.2 Batch Number : -
1.3 Expired Date : -
1.4 Customer Sample(s) Identity : -
1.5 Lab Sample ID : -
1.6 Matrix : Powder

II Results



This report may not be reproduced for any reason except in full and with permission from
PT Biotek Rekayasa Indonesia
Please read full-length Terms and Conditions in the first page



Data Interpretation

The $^1\text{H-NMR}$ spectrum of the sample shows signals consistent with the characteristic proton resonances of **mitragynine**, confirming the identity of the material. The observed chemical shifts and signal patterns correspond to the expected structural features of mitragynine.

Some expected proton signals are partially or not clearly observable due to **signal overlap with solvent resonances (DMSO- d_6)** and **residual water impurities**, which is common for this solvent system and does not affect identity confirmation.

A minor, low-intensity signal observed at approximately δ **0.75 ppm** is attributed to a trace impurity. The signal intensity is minimal and considered **insignificant**, having no impact on the qualitative identification of mitragynine.

Overall, the NMR data confirm that the sample is **consistent with mitragynine** and meets qualitative identity requirements.

ORIGINAL

Approved by,



BIOTEK REKAYASA INDONESIA

Firmansyah Karim
Director

Monday, 09th February 2026